ILCA GUIDANCES

HomeEducationILCA GUIDANCES

Transarterial Chemoembolisation (TACE) Consensus Guidance

Coming soon!

Biomarker Development for Hepatocellular Carcinoma

There is an urgent clinical need for new biomarkers in hepatocellular carcinoma, including better tools for early tumor detection and prediction of response to systemic therapies.

The International Liver Cancer Association has put together an exceptional team of experts led by Drs. Villanueva and Singal, who recently published a white paper with recommendations on the design, interpretation and reporting of biomarker studies in hepatocellular carcinoma. This addresses the much needed guidance for academia and industry on the best approach to develop new biomarkers for this devastating disease.

ILCA Systemic Therapy Guidance
The past few years have witnessed huge progress in the treatment of advanced HCC and the therapeutic landscape has been transformed. In order to provide comprehensive, up-to-date and readily accessible information about the latest treatment, ILCA have developed on-line guidance. The guidance has been launched at the ILCA 2020 conference during which Tim Meyer, UCL Cancer Institute, University College in London, UK and Robin Kate Kelley, Associate Professor University of California, San Francisco, USA  have presented the key features as:
  • Interactive therapeutic algorithm
  • Summary of and links to key data that provide the evidence base for current therapy
  • Focussed discussion on clinical decision making according to specific clinical contexts

LEAVE YOUR COMMENTS AND SUGGESTIONS:

Your email address will not be published. Required fields are marked *

  • UPCOMING WEBINAR: Systemic Therapy of CCA. Patho-molecular profile meets treatment choices. 27 September 2021.
  • WEBINAR: Primary and acquired resistance to immunotherapy in HCC: from research to practice and viceversa. 11 November 2021.